Nakamura, Yoshiaki http://orcid.org/0000-0002-5241-6855
Watanabe, Jun http://orcid.org/0000-0002-7187-3664
Akazawa, Naoya http://orcid.org/0000-0002-2891-6550
Hirata, Keiji
Kataoka, Kozo http://orcid.org/0000-0003-2043-8184
Yokota, Mitsuru
Kato, Kentaro
Kotaka, Masahito
Kagawa, Yoshinori http://orcid.org/0000-0001-6876-4507
Yeh, Kun-Huei http://orcid.org/0000-0002-7306-174X
Mishima, Saori
Yukami, Hiroki
Ando, Koji http://orcid.org/0000-0002-0149-1505
Miyo, Masaaki http://orcid.org/0000-0002-8627-1308
Misumi, Toshihiro
Yamazaki, Kentaro
Ebi, Hiromichi http://orcid.org/0000-0003-3155-7576
Okita, Kenji
Hamabe, Atsushi http://orcid.org/0000-0001-5535-3514
Sokuoka, Hiroki
Kobayashi, Satoshi
Laliotis, George
Aushev, Vasily N. http://orcid.org/0000-0001-8003-358X
Sharma, Shruti
Jurdi, Adham http://orcid.org/0000-0002-2985-3053
Liu, Minetta C. http://orcid.org/0000-0002-8206-5232
Aleshin, Alexey
Rabinowitz, Matthew
Bando, Hideaki http://orcid.org/0000-0001-5041-2765
Taniguchi, Hiroya
Takemasa, Ichiro
Kato, Takeshi
Kotani, Daisuke http://orcid.org/0000-0002-4196-555X
Mori, Masaki
Yoshino, Takayuki http://orcid.org/0000-0002-0489-4756
Oki, Eiji http://orcid.org/0000-0002-9763-9366
Article History
Received: 15 July 2024
Accepted: 19 August 2024
First Online: 16 September 2024
Competing interests
: Y.N. reports advisory roles with Guardant Health Pte Ltd., Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Exact Sciences Corporation and Gilead Sciences, Inc.; speakers’ bureau from Guardant Health Pte Ltd., MSD K.K., Eisai Co., Ltd., Zeria Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., CareNet, Inc., Hisamitsu Pharmaceutical Co., Inc., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Becton, Dickinson and Company and Guardant Health Japan Corp.; research funding from Seagen, Inc., Genomedia, Inc., Guardant Health AMEA, Inc., Guardant Health, Inc., Tempus Labs, Inc., Roche Diagnostics K.K., Daiichi Sankyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. J.W. reports receiving honoraria for lectures from Johnson & Johnson, Medtronic, Eli Lilly and Takeda Pharmaceuticals and receiving research funding from Medtronic, AMCO, TERUMO and Stryker Japan, all outside the submitted work. N.A. reports nothing to declare. K.H. reports nothing to declare. K. Kataoka reports speakers’ bureau from Merck Biopharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan Co., Ltd. and Guardant Health Japan Corp. and research funding from Sysmex. M.Y. reports receipt of personal fees and honoraria for lectures from Medtronic, Johnson & Johnson, INTUITIVE, Eli Lilly, Taiho, Merck KGaA, Takeda and Daiichi Sankyo. K. Kato reports nothing to declare. M.K. reports speakers’ bureau from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly and Yakult Honsha. Y.K. reports speakers’ bureau from Guardant Health Pte Ltd., MSD K.K., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. and Ono Pharmaceutical Co., Ltd. K.H.Y. reports payment or honoraria for lectures, presentations and speakers’ bureaus from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd, TTY Biopharm Co. Ltd., OEP Group Co., Ltd., Bristol Myers Squibb, Amgen, Inc., Bayer Co., Ltd., Daiichi Sankyo Co., Ltd., Merck Biopharma Co., Ltd., Novartis Co., Ltd. and CStone Pharmaceuticals Co., Ltd. and advisory roles with Merck & Co., Inc, Pfizer Inc., Pierre Fabre, Ltd. and AstraZeneca. S.M. reports honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd. and Eli Lilly. H.Y. reports nothing to declare. K.A. reports nothing to declare. M. Miyo reports nothing to declare. T.M. reports advisory role with Anaut, Inc. and Fujifilm Corporation and speakers’ bureau from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd. and Miyarisan Pharmaceutical Co., Ltd. K.Y. reports speakers’ bureau from Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Yakult Honsha Co., Ltd., Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., MSD Co., Ltd. and Bristol Myers Squibb and research funding from Taiho Pharmaceutical Co., Ltd. H.E. reports honoraria from Amgen, Chugai Pharmaceutical Co., Ltd., Guardant Health Japan Corp., Incyte Japan Co., Ltd., Merck Serono Co., Ltd., Ono Pharmaceutical Co., Ltd. and Konica Minolta Co, Ltd. and research funding from Astellas Pharmaceutical Co., Ltd. K.O. reports speakers’ bureau from Taiho Pharmaceutical Co., Ltd. A.H. reports receiving honoraria for lectures from Medtronic, Johnson & Johnson, Merck Biopharma Co., Ltd., Eli Lilly and Fujifilm Corporation. H.S. reports nothing to declare. S.K. is a full-time employee of EPS Corporation. G.L., V.N.A., S.S. and A.J. are employees of Natera, Inc., with stock or options to own stock. M.C.L. is an employee of Natera, Inc., with stock or options to own stock, and further reports grants/contracts (funding to institution: Mayo Clinic) from Eisai, Exact Sciences Corporation, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics and Tesaro; travel support reimbursement from AstraZeneca, Genomic Health and Ionis; and ad hoc advisory board meetings (all funds to Mayo Clinic; no personal compensation) from AstraZeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics and Syndax. A.A. is an employee of Natera, Inc., with a leadership position and stock or options to own stock. M.R. reports employment, leadership position, stock and other ownership interests and consulting and advisory role at Natera, Inc., MyOme and Marble Therapeutics and research funding, patents/royalties/other intellectual property and travel/accommodations/expenses from Natera, Inc. and MyOme. H.B. reports research funding from Ono Pharmaceutical and honoraria from Ono Pharmaceutical, Eli Lilly Japan and Taiho Pharmaceutical. H.T. reports speakers’ bureau from MSD K.K, Merck Biopharma Co., Ltd., Takeda, Taiho, Eli Lilly Japan, Bristol Myers Squibb Japan, Chugai Pharmaceutical, Ono Yakuhin and Amgen and research funding from Takeda and Daiichi Sankyo. I.T. reports speakers’ bureau from Medtronic, Johnson & Johnson, Intuitive, Medicaroid and Eli Lilly and research funding from Medtronic and Sysmex. T.K. reports nothing to declare. D.K. reports honoraria from Takeda, Chugai, Eli Lilly, MSD, Ono Pharmaceutical, Seagen, Guardant Health, Eisai, Taiho, Bristol Myers Squibb, Daiichi Sankyo, Pfizer, Merck Biopharma Co., Ltd. and Sysmex and research funding from Ono Pharmaceutical, MSD, Novartis, Servier, Janssen, IQVIA, Syneoshealth, CIMIC and Cimicshiftzero. M. Mori reports nothing to declare. T.Y. reports honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical, Merck Biopharma Co., Ltd., Bayer Yakuhin, Ono Pharmaceutical and MSD K.K; consulting fee from Sumitomo Corp.; and research funding from Amgen, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia, Medical & Biological Laboratories, Merus N.V., Molecular Health GmbH, MSD, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Roche Diagnostics, Sanofi, Sysmex, Taiho Pharmaceutical and Takeda Pharmaceutical. E.O. reports speakers’ bureau from Chugai Pharmaceutical Co., Ltd., Bristol Meyers Squibb, Ono Pharmaceutical Co., Ltd., Eli Lilly and Takeda Pharmaceutical Co., Ltd.; research funding from Guardant Health, Inc.; and an advisory role with GlaxoSmithKline.